The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
Open accessPublished version of a preprint
Abstract
Tumor genetic testing is standard of care for patients with advanced lung adenocarcinoma, but the fraction of patients who derive clinical benefit remains undefined. Here, we report the experience of 860 patients with metastatic lung adenocarcinoma analyzed prospectively for mutations in >300 cancer-associated genes. Potentially actionable genetic events were stratified into one of four levels based upon published clinical or laboratory evidence that the mutation in question confers increased sensitivity to standard or investigational therapies. Overall, 37.1% (319/860) of patients received a matched therapy guided by their tumor molecular profile. Excluding alterations associated with standard-of-care therapy, 14.4% (69/478) received matched therapy, with a clinical benefit of 52%. Use of matched therapy was strongly influenced by the level of preexistent clinical evidence that the mutation identified predicts for drug response. Analysis of genes mutated significantly more often in tumors without known actionable mutations nominated STK11 and KEAP1 as possible targetable mitogenic drivers. Significance: An increasing number of therapies that target molecular alterations required for tumor maintenance and progression have demonstrated clinical activity in patients with lung adenocarcinoma. The data reported here suggest that broader, early testing for molecular alterations that have not yet been recognized as standard-of-care predictive biomarkers of drug response could accelerate the development of targeted agents for rare mutational events and could result in improved clinical outcomes. Cancer Discov; 7(6); 596–609. ©2017 AACR. See related commentary by Liu et al., p. 555. This article is highlighted in the In This Issue feature, p. 539
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Inactivating mutations or loss of STK11/LKB1, which define one of the major genomic sub-groups of KRAS-mutant lung cancers1,19,62, are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade9,63 and poor overall prognosis64.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [62]
Experimental — accuracy not yet measuredIn the citing paper
“KRAS mutations predominate in NSCLCs, accounting for ~78% of all RAS mutations found in such tumours17. The activating missense KRAS mutations that occur in ~25% of NSCLCs19–23 are typically mutually exclusive with other clinically actionable driver mutations, such as those in EGFR, BRAF and ALK24.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [21]
In the citing paper
“Importantly, large-scale profiling studies utilizing either whole exome sequencing or broad targeted sequencing panels in NSCLC tumors have revealed multiple non-random patterns of co-occurring or mutually exclusive mutations, which typically vary depending on the particular oncogenic driver mutation15, 34, 58–62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
In the citing paper
“Somatic mutations in LKB1 and KEAP1 significantly co-occur with mutant KRAS and with each other in NSCLC15, 59, 63, 91.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
In the citing paper
“Landmark large scale sequencing studies have established a census of major KRAS co-mutations in both early-stage and advanced LUAD15, 34, 59, 62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
In the citing paper
“Activating mutations in KRAS are the most prevalent oncogenic driver event in both early-stage and metastatic LUAD, occurring in 25–32% of tumors34, 59, 60, 62, 67.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
In the citing paper
“Although EGFR –mutant tumors represent the prototypical oncogene-addicted LUAD subgroup that spearheaded adoption of the single-driver model, the overwhelming majority of EGFR-mutant lung tumors harbor one or more co-mutations, even when the analysis is limited to pre-defined sets of cancer-relevant genes within established panels (FoundationOne, Guardant360, MSK-IMPACT)15, 59, 72, 73.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Self-citationIntegrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationComprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Self-citationFirst-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Self-citationUsing Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- OncoKB.org, 2016, Precision Oncology Knowledge Base [Internet]
- Banno, 2016, : 10.1111/.12980, Sensitivities to various EGFR-TKIs of uncommon EGFR mutations L861Q and S768I: what is the optimal EGFR-TKI?, Cancer Sci · DOI
Cited by
Sorted by citations
Items 101–200 of 645
Negrao, M. V., Raymond, V. M., Lanman, R. B., Robichaux, J. P., He, J., Nilsson, M. B., Ng, P. K., Amador, B. E., Roarty, E. B., Nagy, R. J., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.021 · Cited by 79
Antitumor Drugs and Their Targets
Dembić, Z. (2020) · Molecules · doi:10.3390/molecules25235776 · Cited by 75
Molecular Pathology of Lung CancerPreprint
Saller, J. J., & Boyle, T. A. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037812 · Cited by 83
Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?
Garinet, S., Laurent‐Puig, P., Blons, H., & Oudart, J. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7060144 · Cited by 71
Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRASG12C
Kettle, J. G., Bagal, S. K., Bickerton, S., Bodnarchuk, M. S., Boyd, S., Breed, J., Carbajo, R. J., Cassar, D. J., Chakraborty, A., Cosulich, S. C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00369 · Cited by 69
Single-Cell RNA Sequencing: Technological Progress and Biomedical Application in Cancer Research
Xu, C., Zheng, Y., & Xu, K. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00777-0 · Cited by 79
Stockhammer, P., Grant, M. J., Wurtz, A., Foggetti, G., Expósito, F., Gu, J., Zhao, H., Choi, J., Chung, S. T., Li, F., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.10.001 · Cited by 67
Santarpia, M., Ciappina, G., Spagnolo, C. C., Squeri, A., Passalacqua, M. I., Aguilar, A., Gonzalez-Cao, M., Giovannetti, E., Silvestris, N., & Rosell, R. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-639 · Cited by 65
The Pleiotropic Role of the KEAP1/NRF2 Pathway in Cancer
Wu, W., & Papagiannakopoulos, T. Y. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055627 · Cited by 70
Current Status, Issues and Future Prospects of Personalized Medicine for Each Disease
Yamamoto, Y., Kanayama, N., Nakayama, Y., & Matsushima, N. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030444 · Cited by 70
Hou, H., Zhu, H., Zhao, H., Yan, W., Wang, Y., Jiang, M., Liu, B., Liu, D., Zhou, N., Zhang, C., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0629 · Cited by 63
Frost, N., Kollmeier, J., Vollbrecht, C., Grah, C., Matthes, B., Pultermann, D., von Laffert, M., Lüders, H., Olive, E., Raspe, M., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-958 · Cited by 61
Mutational landscape and characteristics of ERBB2 in non‐small cell lung cancer
Wei, X., Gao, X., Zhang, X., Yang, J., Chen, Z., Wu, Y.-L. L. C., & Zhou, Q. H. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13419 · Cited by 62
Hou, J., Li, H., Ma, S., He, Z., Yang, S., Hao, L., Zhou, H., Zhang, Z., Han, J., Wang, L., et al. (2022) · Biomarker Research · doi:10.1186/s40364-022-00372-6 · Cited by 62
Imaging of Precision Therapy for Lung Cancer: Current State of the Art
Park, H., Sholl, L. M., Hatabu, H., Awad, M. M., & Nishino, M. (2019) · Radiology · doi:10.1148/radiol.2019190173 · Cited by 61
Palmero, R., Taus, Á., Viteri, S., Majem, M., Carcereny, E., Garde, J., Felip, E., Nadal, E., Malfettone, A., Sampayo-Cordero, M., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00241 · Cited by 60
Choudhury, N. J., Schoenfeld, A. J., Flynn, J. R., Falcon, C. J., Rizvi, H. A., Rudin, C. M., Kris, M. G., Arcila, M. E., Heller, G., Yu, H. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4650 · Cited by 60
Self-citationTumor biomarker testing in non-small-cell lung cancer: A decade of change
VanderLaan, P. A., Rangachari, D., Majid, A., Parikh, M. S., Gangadharan, S. P., Kent, M. S., McDonald, D. C., Huberman, M. S., Kobayashi, S. S., & Costa, D. B. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.01.002 · Cited by 60
The role of the SWI/SNF chromatin remodelling complex in the response to DNA double strand breaks
Harrod, A., Lane, K. A., & Downs, J. A. (2020) · DNA repair · doi:10.1016/j.dnarep.2020.102919 · Cited by 60
Li, X.-M., Li, W., Lin, J., Yan, H., Tu, H., Chen, H., Wang, B.-C., Wang, Z., Zhou, Q. H., Zhang, X., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.11.001 · Cited by 63
Liu, X., Li, Z., Wang, Z., Liu, F., Zhang, L., Ke, J., Xu, X., Zhang, Y., Yuan, Y., Wei, T., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-0763 · Cited by 63
Self-citationCui, C., Liu, Y., Gerloff, D., Rohde, C., Pauli, C., Köhn, M., Misiak, D., Oellerich, T., Schwartz, S., Schmidt, L., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01570-y · Cited by 60
Wiesweg, M., Kasper, S., Worm, K., Herold, T., Reis, H., Sara, L., Metzenmacher, M., Abendroth, A., Darwiche, K., Aigner, C., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0634-0 · Cited by 55
Caeser, R., Egger, J. V., Chavan, S. S., Socci, N. D., Jones, C. B., Kombak, F. E., Asher, M., Roehrl, M. H. A., Shah, N., Allaj, V., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29794-4 · Cited by 56
Self-citationLi, M. S. C., Mok, K. K. S., & Mok, T. S. K. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-4444 · Cited by 68
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer
Wang, Z., Xing, Y., Li, B., Li, X., Liu, B., & Wang, Y. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00107-x · Cited by 62
Self-citationCNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome
Ou, S. I., & Zhu, V. W. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.02.025 · Cited by 55
Turner, S. R., Buonocore, D. J., Desmeules, P., Rekhtman, N., Doğan, S., Lin, O., Arcila, M. E., Jones, D. R., & Huang, J. G. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.03.003 · Cited by 54
Self-citationRemón, J., Lacroix, L., Jovelet, C., Caramella, C., Howarth, K., Plagnol, V., Rosenfeld, N., Morris, C. D., Mezquita, L., Pannet, C., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00211 · Cited by 54
Burns, T. F., Borghaei, H., Ramalingam, S. S., Mok, T. S. K., & Peters, S. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00744 · Cited by 58
How to read a next-generation sequencing report—what oncologists need to know
Schmid, S., Jochum, W., Padberg, B., Demmer, I., Mertz, K. D., Joerger, M., Britschgi, C., Matter, M. S., Rothschild, S. I., & Omlin, A. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100570 · Cited by 53
Jin, R., Liu, C., Zheng, S., Wang, X., Feng, X., Li, H., Sun, N., & He, J. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0121 · Cited by 55
IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer
Liao, H., Chang, X., Gao, L., Ye, C., Qiao, Y., Xie, L., Lin, J., Cai, S., & Dong, H. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04365-3 · Cited by 55
Liu, X., Mei, W., Zhang, P., & Zeng, C. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107123 · Cited by 51
ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancer
Rosas, G., Ruiz, R., Araujo, J. M., Pinto, J. A., & Mas, L. A. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.02.006 · Cited by 53
Genomics of adult and pediatric solid tumors.
Rahal, Z., Abdulhai, F., Kadara, H. N., & Saab, R. H. (2018) · Europe PMC (PubMed Central) · Cited by 52
Lung cancer research and treatment: global perspectives and strategic calls to action
Meyer, M., Peters, S., Mok, T. S. K., Lam, S. C., Yang, P., Aggarwal, C., Brahmer, J. R., Dziadziuszko, R., Felip, E., Ferris, A. A., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.10.006 · Cited by 55
Self-citationRemón, J., Hendriks, L. E. L., Cabrera, C., Reguart, N., & Besse, B. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.10.006 · Cited by 49
Precision oncology: separating the wheat from the chaff
Remón, J., & Dienstmann, R. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000446 · Cited by 49
Toward Atomistic Modeling of Irreversible Covalent Inhibitor Binding Kinetics
Yu, H. S., Gao, C., Lupyan, D., Wu, Y., Kimura, T., Wu, C., Jacobson, L., Harder, E., Abel, R., & Wang, L. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00268 · Cited by 39
Self-citationRoles of TrkC Signaling in the Regulation of Tumorigenicity and Metastasis of Cancer
Jin, W. (2020) · Cancers · doi:10.3390/cancers12010147 · Cited by 47
Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
Fujino, T., Suda, K., & Mitsudomi, T. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1791821 · Cited by 49
Miller, T. E., Yang, M., Bajor, D. J., Friedman, J. D., Chang, R. Y. C., Dowlati, A., Willis, J. E., & Sadri, N. (2018) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205396 · Cited by 50
CNV Detection from Circulating Tumor DNA in Late Stage Non-Small Cell Lung Cancer Patients
Peng, H., Lŭ, L., Zhou, Z., Liu, J., Zhang, D., Nan, K., Zhao, X., Li, F., Tian, L., Hua, D., et al. (2019) · Genes · doi:10.3390/genes10110926 · Cited by 49
Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing
Conde, E., Rojo, F., Gómez‐Román, J., Enguita, A. B., Abdulkader, I., González, A. M., Lozano, D., Mancheño, N., Salas, C., Salido, M., et al. (2021) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2021-207490 · Cited by 47
Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity
Mansouri, S., Heylmann, D., Stiewe, T., Kracht, M., & Savai, R. (2022) · eLife · doi:10.7554/elife.79895 · Cited by 45
On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
Lindsay, C. R., Garassino, M. C., Nadal, E., Öhrling, K., Scheffler, M., & Mazières, J. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.07.005 · Cited by 46
Zugazagoitia, J., Biosca, M., Oliveira, J., Olmedo, M. E., Dómine, M., Nadal, E., Ruffinelli, J. C., Muñoz, N., Luna, A. M., Hernández, B., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.02431-2017 · Cited by 44
Shen, R., Martin, A. S., Ni, A., Hellmann, M. D., Arbour, K. C., Jordan, E., Arora, A., Ptashkin, R. N., Zehir, A., Kris, M. G., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00307 · Cited by 43
Self-citationZhao, S., Zhang, Z., Zhan, J., Zhao, X., Chen, X., Xiao, L., Wu, K., Ma, Y., Li, M., Yang, Y., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02089-z · Cited by 43
Son, J., Jang, J., Beyett, T. S., Eum, Y., Haikala, H. M., Verano, A. L., Lin, M., Hatcher, J. M., Kwiatkowski, N. P., Eser, P. Ö., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2693 · Cited by 47
Jakobsen, J. N., Santoni-Rugiu, E., Grauslund, M., Melchior, L., & Sørensen, J. B. (2018) · Oncotarget · doi:10.18632/oncotarget.25490 · Cited by 42
Wang, J., Lam, D., Yang, J., & Hu, L. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-022-02952-5 · Cited by 43
Clinical tumour sequencing for precision oncology: time for a universal strategy
Cheng, M. L., Berger, M. F., Hyman, D. M., & Solit, D. B. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0043-2 · Cited by 42
Self-citationDefining molecular risk in ALK+ NSCLC
Christopoulos, P., Budczies, J., Kirchner, M., Dietz, S., Sültmann, H., Thomas, M., & Stenzinger, A. (2019) · Oncotarget · doi:10.18632/oncotarget.26886 · Cited by 42
Zhou, J. H., Sánchez-Vega, F., Caso, R., Tan, K. S., Brandt, W. S., Jones, G. D., Shi, Y., Adusumilli, P. S., Bott, M. J., Huang, J. G., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1651 · Cited by 42
Self-citationIn-silico design of peptide inhibitors of K-Ras target in cancer disease
Ghufran, M., Rehman, A. U., Shah, M., Ayaz, M., Ng, H. L., & Wadood, A. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1704880 · Cited by 42
Huang, L., Zhang, S., Han, C., & Ma, J. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.01.014 · Cited by 46
Xu, Q., Wang, C., Zhou, J., Xu, Z.-M., Gao, J., Sui, P., Walsh, C. P., Ji, H., & Xu, G. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2107599119 · Cited by 41
Self-citationLegras, A., Barritault, M., Tallet, A., Fabre, E., Guyard, A., Rance, B., Digan, W. E., Pécuchet, N., Leprieur, E. G., Julié, C., et al. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.04.002 · Cited by 42
Wang, Q., Mehmood, A., Wang, H., Xu, Q., Xiong, Y., & Wei, D. (2019) · Molecules · doi:10.3390/molecules24101951 · Cited by 41
Saigí, M., Alburquerque-Béjar, J. J., & Sánchez‐Céspedes, M. (2019) · Oncogene · doi:10.1038/s41388-019-0855-x · Cited by 40
Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients
Liao, B.-C., Griesing, S., & Yang, J. C. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919890286 · Cited by 40
Yang, S., Chang, J. C., Leduc, C., Tan, K. S., Doğan, S., Benayed, R., Borsu, L. A., Offin, M. D., Drilon, A. E. D. C., Travis, W. D., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.03.023 · Cited by 42
Self-citationLeal, J. L., Alexander, M., Itchins, M., Wright, G. M., Kao, S., Hughes, B. G. M., Pavlakis, N., Clarke, S. J., Gill, A. J., Ainsworth, H., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.04.009 · Cited by 41
Kohsaka, S., Hayashi, T., Nagano, M., Ueno, T., Kojima, S., Kawazu, M., Shiraishi, Y., Kishikawa, S., Suehara, Y., Takahashi, F., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.021 · Cited by 41
Akamatsu, H., Murakami, H., Harada, H., Shimizu, J., Hayashi, H., Daga, H., Hasegawa, Y., Kim, Y. H., Kato, T., Tokunaga, S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.05.019 · Cited by 41
Liu, J., Yang, H., Deng, S., Hu, Z., Chen, W., Yan, W., Hou, R., Li, Y., Xian, R., Xie, Y., et al. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00890-x · Cited by 38
Kettle, J. G., Bagal, S. K., Barratt, D. G., Bodnarchuk, M. S., Boyd, S., Braybrooke, E. L., Breed, J., Cassar, D. J., Cosulich, S. C., Davies, M., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00746 · Cited by 38
Yang, S., Gedvilaite, E., Ptashkin, R. N., Chang, J. C., Ziegler, J., Mata, D. A., Villafania, L. B., Nafa, K., Hechtman, J. F., Benayed, R., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.10.004 · Cited by 38
Self-citationChen, C., Lin, C., Pei, Y., Ma, D., Liao, L., Li, S., Fan, L., Di, G., Wu, S., Liu, X., et al. (2023) · Cell Discovery · doi:10.1038/s41421-023-00614-3 · Cited by 43
Self-citationRen, Y., Chen, J., Chen, P., Hao, Q., Cheong, L.-K., Tang, M., Hong, L., Hu, X., Yap, C. T., Bay, B., et al. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.02.018 · Cited by 41
Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population
Dang, A.-T. H., Tran, V.-U., Tran, T.-T., Pham, H.-A. T., Le, D.-T. V., Nguyen, L., Nguyen, N. V., Nguyen, T.-H. T., Nguyen, C. V., Le, H. T., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-59744-3 · Cited by 37
2020 Innovation-Based Optimism for Lung Cancer Outcomes
Schenk, E. L., Patil, T., Pacheco, J. M., & Bunn, P. A. (2020) · The Oncologist · doi:10.1002/onco.13590 · Cited by 37
Precision oncology in non-small-cell lung cancer: opportunities and challenges
Kim, C., & Giaccone, G. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0008-0 · Cited by 35
Gini, B., Thomas, N. J., & Blakely, C. M. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.03.78 · Cited by 38
Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy
Recondo, G., Mahjoubi, L., Maillard, A., Loriot, Y., Bigot, L., Facchinetti, F., Bahleda, R., Gazzah, A., Hollebecque, A., Mezquita, L., et al. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-00130-7 · Cited by 38
Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples
Tomlins, S. A., Hovelson, D. H., Suga, J. M., Anderson, D. M., Koh, H. A., Dees, E. C., McNulty, B., Burkard, M. E., Guarino, M. J., Khatri, J., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00472 · Cited by 36
Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study
Sun, H., Ren, P., Chen, Y., Lan, L., Yan, Z., Yang, Y., Wang, B., Wang, C., Li, Y., Li, L., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10637-4 · Cited by 36
Choudhury, N. J., Lavery, J. A., Brown, S., de Bruijn, I., Jee, J., Tran, T. N., Rizvi, H. A., Arbour, K. C., Whiting, K. A., Shen, R., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0580 · Cited by 36
Self-citationAnakura, M., Nachankar, A., Kobayashi, D., Amornwichet, N., Hirota, Y., Shibata, A., Oike, T., & Nakano, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153635 · Cited by 33
Choudhury, N. J., Schneider, J. L., Patil, T., Zhu, V. W., Goldman, D. A., Yang, S., Falcon, C. J., Do, A., Nie, Y., Plodkowski, A. J., et al. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100187 · Cited by 33
Self-citationSimons, M., Retèl, V. P., Ramaekers, B. L. T., Butter, R., Mankor, J. M., Paats, M. S., Aerts, J. G. J. V., Mfumbilwa, Z. A., Roepman, P., Coupé, V. M. H., et al. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01073-y · Cited by 34
Mack, P. C., Klein, M., Ayers, K. L., Zhou, X., Guin, S., Fink, M. Y., Rossi, M. R., AI-Kateb, H., O'Connell, T. J., Hantash, F. M., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac035 · Cited by 33
The mechanistic insights of the antioxidant Keap1-Nrf2 pathway in oncogenesis: a deadly scenario
Mukherjee, A. G., & Gopalakrishnan, A. V. (2023) · Medical Oncology · doi:10.1007/s12032-023-02124-4 · Cited by 33
The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy
Friedlaender, A., Tsantoulis, P. K., Chevallier, M., Vito, C. D., & Addeo, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.644472 · Cited by 33
Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer
Dagogo‐Jack, I., Azzolli, C. G., Fintelmann, F. J., Mino-Kenudson, M. A., Farago, A. F., Gainor, J. F., Jiang, G. Y., Piotrowska, Z., Heist, R. S., Lennes, I. T., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00299 · Cited by 33
Direct K-Ras Inhibitors to Treat Cancers: Progress, New Insights, and Approaches to Treat Resistance
Nussinov, R., & Jang, H. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022823-113946 · Cited by 32
Second Primary Lung Cancer – An Emerging Issue in Lung Cancer Survivors
Jensen, S. Ø., Moore, D. A., Surani, A. A., Crosbie, P. A. J., Rosenfeld, N., & Rintoul, R. C. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.07.014 · Cited by 32
GATA3-induced vWF upregulation in the lung adenocarcinoma vasculature
Xu, Y., Pan, S., Liu, J., Dong, F., Cheng, Z., Zhang, J., Qi, R., Zang, Q., Zhang, W., Wang, X., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22806 · Cited by 31
Signorovitch, J., Zhou, Z., Ryan, J., Anhorn, R., & Chawla, A. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1549056 · Cited by 31
Yoshimura, K., Inoue, Y., Tsuchiya, K., Karayama, M., Yamada, H., Iwashita, Y., Kawase, A., Tanahashi, M., Ogawa, H., Inui, N., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.01.005 · Cited by 32
Zeng, L., Xiao, L., Jiang, W., Yang, H., Hu, D., Chen, X., Li, Y., Zhou, C., Xiong, Y., Liu, L., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.01.009 · Cited by 31
Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer
Heřmanová, I., Zúñiga-García, P., Caro‐Maldonado, A., Fernández‐Ruiz, S., Salvador, F., Martín-Martín, N., Zabala‐Letona, A., Núnez-Ollé, M., Torrano, V., Camacho, L., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191787 · Cited by 29
Gene Expression Profiling as a Potential Tool for Precision Oncology in Non-Small Cell Lung Cancer
Hijazo‐Pechero, S., Alay, A., Marín, R., Vilariño, N., Muñoz‐Pinedo, C., Villanueva, A., Santamarı́a, D., Nadal, E., & Solé, X. (2021) · Cancers · doi:10.3390/cancers13194734 · Cited by 30
Tayoun, T., Faugeroux, V., Oulhen, M., Déas, O., Michels, J., Brullé, L., Cairo, S., Scoazec, J., Marty, V., Aberlenc, A., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.155804 · Cited by 33
Feng, Y., Zhang, T., Zhang, Z., Liang, Y., Wang, H., Chen, Y., Yu, X., Song, X., Mao, Q., Xia, W., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06047-w · Cited by 31
Huang, D., Wang, J., Chen, L., Jiang, W., Inuzuka, H., Simon, D. K., & Wei, W. (2025) · Molecules · doi:10.3390/molecules30081731 · Cited by 31
Waterhouse, D. M., Tseng, W.-Y., Espirito, J. L., & Robert, N. J. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.05.006 · Cited by 30
Zhao, Y., Yang, Y., Sheng, H., Tang, Q., Han, L., Wang, S., & Wu, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.851680 · Cited by 30
Metadata
- Authors
- Jordan, E. J., Kim, H. R., Arcila, M. E., Barron, D., Chakravarty, D., Gao, J., Chang, M. T., Ni, A., Kundra, R., Jonsson, P., Jayakumaran, G., Gao, S. P., Johnsen, H. C., Hanrahan, A. J., Zehir, A., Rekhtman, N., Ginsberg, M. S., Li, B. T., Yu, H. A., Paik, P. K., Drilon, A., Hellmann, M. D., Reales, D. N., Benayed, R., Rusch, V. W., Kris, M. G., Chaft, J. E., Baselga, J., Taylor, B. S., Schultz, N., Rudin, C. M., Hyman, D. M., Berger, M. F., Solit, D. B., Ladanyi, M., & Riely, G. J.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- 6Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
- 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
- Corresponding author
- Riely, Gregory J.
- ORCID
- Jordan, Emmet J.
- Kim, Hyunjae R.
- Arcila, Maria E.
- Chakravarty, Debyani
- Gao, JianJiong
- Kundra, Ritika
- Jonsson, Philip
- Jayakumaran, Gowtham
- Zehir, Ahmet
- Rekhtman, Natasha
- Ginsberg, Michelle S.
- Li, Bob T.
- Yu, Helena A.
- Paik, Paul K.
- Drilon, Alexander
- Hellmann, Matthew D.
- Reales, Dalicia N.
- Benayed, Ryma
- Rusch, Valerie W.
- Kris, Mark G.
- Chaft, Jamie E.
- Taylor, Barry S.
- Schultz, Nikolaus
- Rudin, Charles M.
- Hyman, David M.
- Berger, Michael F.
- Solit, David B.
- Ladanyi, Marc
- Riely, Gregory J.
- Venue
- Cancer Discovery
- Published
- 2017-06-01
- Volume
- 7
- Issue
- 6
- Pages
- 596-609
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC5482929
- OpenAlex
- W2603411876
- Cited by
- 643
- References
- 49
- Citations by year
- 2026: 30 · 2025: 40 · 2024: 65 · 2023: 99 · 2022: 94 · 2021: 101 · 2020: 79 · 2019: 65 · 2018: 55 · 2017: 12
- FWCI
- 47.73
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR002384)
- National Cancer Institute (P30CA008748)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- lung adenocarcinoma, metastatic lung cancer, actionable mutations, targeted therapy, predictive biomarkers, drug response, STK11, Keap1, clinical benefit, molecular profiling
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Adolescent, Adult, Aged, Female, Genetic Testing, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Biomarkers, Tumor, Young Adult, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
